Hospital News and Research

RSS

Experimental heart failure drug has little impact on exercise tolerance

Heart failure patients taking the investigational drug omecamtiv mecarbil, which has been previously shown to improve long-term outcomes, see little impact on their ability to exercise compared to a placebo, according to a study supported by the Duke Clinical Research Institute.

4 Apr 2022

SARS-CoV-2 prevalence during the initial period of SARS-CoV-2 Omicron variant emergence in Finland

A recent study presented the rapid spike in COVID-19 seroprevalence during the emergence of the Omicron variant in Finland.

4 Apr 2022

Value of information analysis on clinical trial data to help approve or reject new COVID-19 drugs

Researchers quantified the cost-effective health benefits of pursuing further research or approving or rejecting COVID-19 drugs based on the existing research using a novel method called VOI analysis.

4 Apr 2022

Acute respiratory distress syndrome may increase death risk among young COVID-19 patients

A new study estimated the risk and prevalence of acute respiratory distress syndrome in hospitalized young adults with SARS-CoV-2 infection.

4 Apr 2022

Novel rapid genetic test could spare 14,000 newborns from lifelong hearing loss

Clinicians and nurses in neonatal intensive care units (NICU) across Manchester University NHS Foundation Trust (MFT) are the world’s first to deploy genedrive’s MT-RNR1 ID Kit, a new rapid genetic point of care test (POCT) to screen babies for the genetic variant m.1555A>G when admitted with suspected sepsis

4 Apr 2022

Study identifies new risk factors for recovery after reconstructive breast surgery

Factors such as anemia and anticoagulants have more impact on hospitalization time after breast reconstruction than "common" risk factors.

4 Apr 2022

COVID-19 study proves ivermectin ineffective

A recent study published in the New England Journal of Medicine investigated the impact of ivermectin, an antiparasitic drug, as an early treatment option among coronavirus disease 2019 (COVID-19) patients.

4 Apr 2022

mRNA-1273 and BNT162b2 COVID-19 vaccines induce slightly different immune responses

In a recent study published in the journal Science, researchers observed differential effector functions of antibodies elicited by Pfizer’s BNT162b2 and Moderna’s messenger ribonucleic acid (mRNA)-1273 coronavirus disease 2019 (COVID-19) vaccines.

4 Apr 2022

How well does the BNT162b2 vaccine protect children and teens against Omicron?

A study published in the New England Journal of Medicine investigated the vaccine efficiency of the Pfizer BioNTech (BNT162b2) vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant in children and adolescents.

4 Apr 2022

Addition of alirocumab to high-intensity statin treatment reduces key measures of plaque vulnerability

Compared with a placebo, the addition of the injectable cholesterol-lowering drug alirocumab to high-intensity statin treatment in patients who have had a heart attack resulted in twofold greater reductions in three key measures of plaque vulnerability that signal risk for future cardiac events, according to research presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Experimental heart failure drug does not improve exercise capacity in HFrEF patients

Patients with heart failure with reduced ejection fraction (HFrEF) did not experience any improvement in their ability to exercise vigorously after taking the experimental heart failure drug omecamtiv mecarbil, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Smartwatch application can be used for atrial fibrillation screening

Atrial fibrillation (AFib) was confirmed in nearly 94% of people who were initially identified to have signs of the heart rhythm disorder by a smartwatch application and who followed up with a clinician, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Investigational drug vupanorsen reduces non-HDL cholesterol by up to 28%

The investigational drug vupanorsen reduced total levels of non-high-density lipoprotein (non-HDL) cholesterol by up to 28% in patients with high cholesterol who were already taking a cholesterol-lowering statin medication, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Experimental siRNA therapy reduces a key driver of heart disease risk by up to 98%

Findings from a new Cleveland Clinic-led phase 1 trial show that an experimental "gene silencing" therapy reduced blood levels of lipoprotein(a), a key driver of heart disease risk, by up to 98%.

3 Apr 2022

New evidence on how salt reduction can benefit heart failure patients

For the past century people with weak hearts have been told to lower their salt intake, but until now there has been little scientific evidence behind the recommendation.

2 Apr 2022

Experimental drug for hypertrophic cardiomyopathy reduces the need for invasive procedures, trial shows

Findings from a Cleveland Clinic-led clinical trial showed that the use of an experimental drug in severely symptomatic, hypertrophic cardiomyopathy patients significantly reduced the need for invasive procedures.

2 Apr 2022

Limiting sodium intake results in improved quality of life for patients with heart failure

Nutrition counseling and strictly limiting salt intake for one year in patients with heart failure resulted in improved quality of life and a slowing in the progression of the disease, but a study presented at the American College of Cardiology's (ACC) 71st Annual Scientific Session found reducing salt intake did not significantly reduce major adverse events or hospitalizations.

2 Apr 2022

Hospital News and Research

Experimental heart failure drug has little impact on exercise tolerance

SARS-CoV-2 prevalence during the initial period of SARS-CoV-2 Omicron variant emergence in Finland

Value of information analysis on clinical trial data to help approve or reject new COVID-19 drugs

Acute respiratory distress syndrome may increase death risk among young COVID-19 patients

Novel rapid genetic test could spare 14,000 newborns from lifelong hearing loss

Study identifies new risk factors for recovery after reconstructive breast surgery

COVID-19 study proves ivermectin ineffective

mRNA-1273 and BNT162b2 COVID-19 vaccines induce slightly different immune responses

How well does the BNT162b2 vaccine protect children and teens against Omicron?

Addition of alirocumab to high-intensity statin treatment reduces key measures of plaque vulnerability

Experimental heart failure drug does not improve exercise capacity in HFrEF patients

Smartwatch application can be used for atrial fibrillation screening

Investigational drug vupanorsen reduces non-HDL cholesterol by up to 28%

Experimental siRNA therapy reduces a key driver of heart disease risk by up to 98%

New evidence on how salt reduction can benefit heart failure patients

Experimental drug for hypertrophic cardiomyopathy reduces the need for invasive procedures, trial shows

Limiting sodium intake results in improved quality of life for patients with heart failure

Domestic violence survivor, UK patient stands and walks for the first time in more than eight years

Study shows significant increase in survival rates of extremely pre-term babies

Study investigates messenger ribonucleic acid-based SARS-CoV-2 vaccine efficacy against SARS-CoV-2 Omicron in Denmark

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News